| Literature DB >> 21527903 |
Y Sterner1, C Törn, H-S Lee, H Larsson, C Winkler, W McLeod, K Lynch, O Simell, A Ziegler, D Schatz, W Hagopian, M Rewers, J-X She, J P Krischer, B Akolkar, A Lernmark.
Abstract
OBJECTIVE: To examine the relationship between high-risk human leukocyte antigen (HLA) genotypes for type 1 diabetes and birth size in combination with prenatal ch aracteristics in different countries. STUDYEntities:
Mesh:
Substances:
Year: 2011 PMID: 21527903 PMCID: PMC3226663 DOI: 10.1038/jp.2011.26
Source DB: PubMed Journal: J Perinatol ISSN: 0743-8346 Impact factor: 3.225
HLA eligibility for FDR and the GP infantsa
| A | DR4-DQA1*030X-DQB1*0302/DR3-DQA1*0501-DQB1*0201 | DQ 2/8 | Y |
| B | DR4-DQA1*030X-DQB1*0302/DR4-DQA1*030X-DQB1*0302 | DQ 8/8 | Y |
| C | DR4-DQA1*030X-DQB1*0302/DR8-DQA1*0401-DQB1*0402 | DQ 4/8 | Y |
| D | DR3-DQA1*0501-DQB1*0201/DR3-DQA1*0501-DQB1*0201 | DQ 2/2 | Y |
Abbreviations: FDR, first degree relative; GP, general population; HLA, human leukocyte antigen; N, not eligible for the Environmental determinants of Diabetes in the Young inclusion; Y, eligible.
DR4 subtyping was used to exclude GP infants with DRB1*0403. DQB1*0304 in place of DQB1*0302 qualifies subjects for the Environmental determinants of Diabetes in the Young inclusion. Subtyping was not required to distinguish DQB1*020X and DQA1*030X subtypes.
Mother height and weight at the end of pregnancy with TEDDY HLA types
| n | n | Pr>∣t∣ | Pr>F | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AvsC | 0.680 | 0.264 | 0.010** | 1.130 | 0.578 | 0.051* | ||||
| BvsC | 5328 | 0.446 | 0.302 | 0.140 | 0.001** | 5255 | 0.853 | 0.662 | 0.198 | <0.0001** |
| DvsC | 1.140 | 0.298 | 0.000** | 3.145 | 0.652 | <0.0001** | ||||
| AvsC | 1.056 | 0.514 | 0.040** | 1.644 | 1.134 | 0.148 | ||||
| BvsC | 2023 | 1.059 | 0.576 | 0.066* | 0.012** | 2007 | 0.844 | 1.274 | 0.508 | 0.042** |
| DvsC | 1.846 | 0.558 | 0.001** | 3.246 | 1.234 | 0.009** | ||||
| AvsC | −0.018 | 0.435 | 0.967 | 0.148 | 0.892 | 0.869 | ||||
| BvsC | 1128 | 0.064 | 0.544 | 0.906 | 0.999 | 1122 | −0.297 | 1.116 | 0.790 | 0.544 |
| DvsC | 0.017 | 0.555 | 0.975 | 1.452 | 1.138 | 0.202 | ||||
| AvsC | 0.904 | 1.252 | 0.471 | 4.153 | 2.979 | 0.164 | ||||
| BvsC | 275 | 0.943 | 1.420 | 0.507 | 0.131 | 274 | 5.397 | 3.376 | 0.111 | 0.216 |
| DvsC | 2.700 | 1.346 | 0.046** | 6.576 | 3.201 | 0.041** | ||||
| AvsC | 0.273 | 0.445 | 0.539 | −2.026 | 0.990 | 0.041** | ||||
| BvsC | 1902 | −0.372 | 0.492 | 0.450 | 0.228 | 1852 | −2.033 | 1.093 | 0.063* | 0.017** |
| DvsC | 0.440 | 0.493 | 0.372 | 0.150 | 1.098 | 0.892 | ||||
Abbreviations: HLA, human leukocyte antigen; PE, multiple regression parameter estimate; Pr>∣t∣, P-value for parameter estimate; Pr>F, P-value for analysis of covariance; TEDDY, the Environmental determinants of Diabetes in the Young.
Additionally adjusted for parental physical characteristics; **P<0.05; *P<0.1.
Father height with TEDDY HLA types
| n | |||||
|---|---|---|---|---|---|
| AvsC | 0.864 | 0.537 | 0.108 | ||
| BvsC | 1495 | 0.292 | 0.614 | 0.634 | 0.015** |
| DvsC | 1.771 | 0.602 | 0.003** | ||
| AvsC | 1.438 | 1.045 | 0.170 | ||
| BvsC | 513 | 0.705 | 1.158 | 0.543 | 0.073* |
| DvsC | 2.740 | 1.127 | 0.015** | ||
| AvsC | −0.501 | 1.196 | 0.676 | ||
| BvsC | 235 | −1.095 | 1.439 | 0.448 | 0.588 |
| DvsC | 1.204 | 1.535 | 0.434 | ||
| AvsC | −0.664 | 2.233 | 0.767 | ||
| BvsC | 87 | 1.314 | 2.645 | 0.621 | 0.764 |
| DvsC | 0.952 | 2.456 | 0.699 | ||
| AvsC | 0.906 | 0.806 | 0.261 | ||
| BvsC | 660 | 0.307 | 0.911 | 0.736 | 0.448 |
| DvsC | 1.252 | 0.896 | 0.163 | ||
Abbreviations: HLA, human leukocyte antigen; PE, multiple regression parameter estimate; Pr>∣t∣, P-value for parameter estimate; Pr>F, P-value for analysis of covariance; TEDDY, the Environmental determinants of Diabetes in the Young.
Additionally adjusted for parental physical characteristics; **P<0.05; *P<0.1.